Commission Regulation (EU) No 605/2014 of 5 June 2014 amending, for the purposes of introducing hazard and precautionary statements in the Croatian language and its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures Text with EEA relevance
Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗
Regulation (EC) No 1272/2008 is amended as follows: (1) Annex III is amended in accordance with Annex I to this Regulation; (2) Annex IV is amended in accordance with Annex II to this Regulation; (3) Annex VI is amended in accordance with Annex III to this Regulation.
1. By way of derogation from Article 3(2), substances and mixtures may, before 1 December 2014 and 1 June 2015 respectively, be classified, labelled and packaged in accordance with this Regulation. 2. By way of derogation from Article 3(2), substances classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 and placed on the market before 1 December 2014, shall not be required to be relabelled and repackaged in accordance with this Regulation until 1 December 2016. 3. By way of derogation from Article 3(2), mixtures classified, labelled and packaged in accordance with Directive 1999/45/EC of the European Parliament and of the Council ( 6 ) or Regulation (EC) No 1272/2008 and placed on the market before 1 June 2015, shall not be required to be relabelled and repackaged in accordance with this Regulation until 1 June 2017. 4. By way of derogation from Article 3(3), the harmonised classifications set out in Annex III to this Regulation may be applied before the date referred to in Article 3(3).
1. This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union . 2. Article 1(1) and (2) shall apply in respect of substances from 1 December 2014 and in respect of mixtures from 1 June 2015. 3. Article 1(3) shall apply from 1 April 2015.
ANNEX I In Part 1 of Annex III, Table 1.1 is amended as follows: (1) in code H229, the following is inserted after the entry corresponding to GA: ‘HR Spremnik pod tlakom: može se rasprsnuti ako se grije.’ (2) in code H230, the following is inserted after the entry corresponding to GA: ‘HR Može eksplozivno reagirati i bez prisustva zraka.’ (3) in code H231, the following is inserted after the entry corresponding to GA: ‘HR Može eksplozivno reagirati i bez prisustva zraka na povišenom tlaku i/ili temperaturi.’
ANNEX II Part 2 to Annex IV is amended as follows: (1) Table 1.2 is amended as follows: (a) in code P210, the following is inserted after the entry corresponding to GA: ‘HR Čuvati odvojeno od topline, vrućih površina, iskri, otvorenih plamena i ostalih izvora paljenja. Ne pušiti.’ (b) in code P223: The following is inserted after the entry corresponding to GA: ‘HR Spriječiti dodir s vodom.’ (c) in code P244, the following is inserted after the entry corresponding to GA: ‘HR Spriječiti dodir ventila i spojnica s uljem i masti.’ (d) in code P251, the following is inserted after the entry corresponding to GA: ‘HR Ne bušiti, niti paliti čak niti nakon uporabe.’ (e) in code P284, the following is inserted after the entry corresponding to GA: ‘HR [U slučaju nedovoljne ventilacije] nositi sredstva za zaštitu dišnog sustava.’ (2) Table 1.3 is amended as follows: (a) in code P310, the following is inserted after the entry corresponding to GA: ‘HR Odmah nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…’ (b) in code P 311, the following is inserted after the entry corresponding to GA: ‘HR Nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…’ (c) in code P312: The following is inserted after the entry corresponding to GA: ‘HR U slučaju zdravstvenih tegoba nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…’ (d) in code P340, the following is inserted after the entry corresponding to GA: ‘HR Premjestiti osobu na svježi zrak i postaviti ju u položaj koji olakšava disanje.’ (e) in code P352, the following is inserted after the entry corresponding to GA: ‘HR Oprati velikom količinom vode/…’ (f) in code P361, the following is inserted after the entry corresponding to GA: ‘HR Odmah skinuti svu zagađenu odjeću.’ (g) in code P362, the following is inserted after the entry corresponding to GA: ‘HR Skinuti zagađenu odjeću.’ (h) in code P364, the following is inserted after the entry corresponding to GA: ‘HR I oprati je prije ponovne uporabe.’ (i) in code P378, the following is inserted after the entry GA: ‘HR Za gašenje rabiti …’ (j) in combined codes P301 + P310, the following is inserted after the entry corresponding to GA: ‘HR AKO SE PROGUTA: odmah nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…’ (k) in combined codes P301 + P312, the following is inserted after the entry corresponding to GA: ‘HR AKO SE PROGUTA: u slučaju zdravstvenih tegoba nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…’ (l) in combined codes P302 + P352, the following is inserted after the entry corresponding to GA: ‘HR U SLUČAJU DODIRA S KOŽOM: oprati velikom količinom vode/…’ (m) in combined codes P303 + P361+P353, the following is inserted after the entry corresponding to GA: ‘HR U SLUČAJU DODIRA S KOŽOM (ili kosom): odmah skinuti svu zagađenu odjeću. Isprati kožu vodom/tuširanjem.’ (n) in combined codes P304 + P340, the following is inserted after the entry corresponding to GA: ‘HR AKO SE UDIŠE: premjestiti osobu na svježi zrak i postaviti ju u položaj koji olakšava disanje.’ (o) in combined codes P308 + P311, the following is inserted after the entry corresponding to GA: ‘HR U SLUČAJU izloženosti ili sumnje na izloženost: nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…’ (p) in combined codes P342 + P311, the following is inserted after the entry corresponding to GA: ‘HR Pri otežanom disanju: nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…’ (q) in combined codes P361 + P364, the following is inserted after the entry corresponding to GA: ‘HR Odmah skinuti svu zagađenu odjeću i oprati je prije ponovne uporabe.’ (r) in combined codes P362 + P364, the following is inserted after the entry corresponding to GA: ‘HR Skinuti zagađenu odjeću i oprati je prije ponovne uporabe.’ (s) in combined codes P370 + P378, the following is inserted after the entry corresponding to GA: ‘HR U slučaju požara: za gašenje rabiti …’
ANNEX III Part 3 of Annex VI is amended as follows: (1) Table 3.1 is amended as follows: (a) the entry corresponding to index number 015-188-00-X is deleted; (b) the entries corresponding to index numbers 006-086-00-6, 015-154-00-4, 015-192-00-1, 601-023-00-4, 601-026-00-0, 603-061-00-7, 605-001-00-5, 605-008-00-3 and 616-035-00-5 are replaced by the following corresponding entries: ‘006-086-00-6 fenoxycarb (ISO); ethyl [2-(4-phenoxyphenoxy)ethyl]carbamate 276-696-7 72490-01-8 Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H400 H410 GHS08 GHS09 Wng H351 H410 M = 1 M = 10 000 015-154-00-4 ethephon; 2-chloroethylphosphonic acid 240-718-3 16672-87-0 Acute Tox. 3 Acute Tox. 4 Acute Tox. 4 Skin Corr. 1C Aquatic Chronic 2 H311 H332 H302 H314 H411 GHS06 GHS05 GHS09 Dgr H311 H332 H302 H314 H411 EUH071 015-192-00-1 tetrakis(2,6-dimethylphenyl)- m -phenylene biphosphate 432-770-2 139189-30-3 Skin Sens. 1 H317 GHS07 Wng H317 601-023-00-4 ethylbenzene 202-849-4 100-41-4 Flam. Liq. 2 Acute Tox. 4* STOT RE 2 Asp. Tox. 1 H225 H332 H373 (hearing organs) H304 GHS02 GHS07 GHS08 Dgr H225 H332 H373 (hearing organs) H304 601-026-00-0 styrene 202-851-5 100-42-5 Flam. Liq. 3 Repr. 2 Acute Tox. 4* STOT RE 1 Skin Irrit. 2 Eye Irrit. 2 H226 H361d H332 H372 (hearing organs) H315 H319 GHS02 GHS08 GHS07 Dgr H226 H361d H332 H372 (hearing organs) H315 H319 * D 603-061-00-7 tetrahydro-2-furylmethanol; tetrahydrofurfuryl alcohol 202-625-6 97-99-4 Repr. 1B Eye Irrit. 2 H360Df H319 GHS08 GHS07 Dgr H360Df H319 605-001-00-5 formaldehyde …% 200-001-8 50-00-0 Carc. 1B Muta. 2 Acute Tox. 3* Acute Tox. 3* Acute Tox. 3* Skin Corr. 1B Skin Sens. 1 H350 H341 H301 H311 H331 H314 H317 GHS08 GHS06 GHS05 Dgr H350 H341 H301 H311 H331 H314 H317 * Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 5 % ≤ C < 25 % Eye Irrit. 2; H319: 5 % ≤ C < 25 % STOT SE 3; H335: C ≥ 5 % Skin Sens. 1; H317: C ≥ 0,2 % B, D 605-008-00-3 acrolein; prop-2-enal; acrylaldehyde 203-453-4 107-02-8 Flam. Liq. 2 Acute Tox. 1 Acute Tox. 2 Acute Tox. 3 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 H225 H330 H300 H311 H314 H400 H410 GHS02 GHS06 GHS05 GHS09 Dgr H225 H330 H300 H311 H314 H410 EUH071 Skin Corr. 1B; H314: C ≥ 0,1 % M = 100 M = 1 D 616-035-00-5 cymoxanil (ISO); 2-cyano- N -[(ethylamino)carbonyl]-2-(methoxyimino)acetamide 261-043-0 57966-95-7 Repr. 2 Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H361fd H302 H373 (blood, thymus) H317 H400 H410 GHS08 GHS07 GHS09 Wng H361fd H302 H373 (blood, thymus) H317 H410 M = 1 M = 1’ (c) the following entries are inserted in accordance with the order of the entries set out in Table 3.1: ‘050-028-00-2 2-ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate 260-829-0 57583-35-4 Repr. 2 Acute Tox. 4 STOT RE 1 Skin Sens. 1A H361d H302 H372 (nervous system, immune system) H317 GHS08 GHS07 Dgr H361d H302 H372 (nervous system, immune system) H317 050-029-00-8 dimethyltin dichloride 212-039-2 753-73-1 Repr. 2 Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 STOT RE 1 Skin Corr. 1B H361d H330 H301 H311 H372 (nervous system, immune system) H314 GHS08 GHS06 GHS05 Dgr H361d H330 H301 H311 H372 (nervous system, immune system) H314 EUH071 601-088-00-9 4-vinylcyclohexene 202-848-9 100-40-3 Carc. 2 H351 GHS08 Wng H351 601-089-00-4 muscalure; cis-tricos-9-ene 248-505-7 27519-02-4 Skin Sens. 1B H317 GHS07 Wng H317 604-090-00-8 4-tert-butylphenol 202-679-0 98-54-4 Repr. 2 Skin Irrit. 2 Eye Dam. 1 H361f H315 H318 GHS08 GHS05 Dgr H361f H315 H318 604-091-00-3 etofenprox (ISO); 2-(4-ethoxyphenyl)-2-methylpropyl 3-phenoxybenzyl ether 407-980-2 80844-07-1 Lact. Aquatic Acute 1 Aquatic Chronic 1 H362 H400 H410 GHS09 Wng H362 H410 M = 100 M = 1 000 606-146-00-7 tralkoxydim (ISO); 2-(N-ethoxypropanimidoyl)-3-hydroxy-5-mesitylcyclohex-2-en-1-one - 87820-88-0 Carc. 2 Acute Tox. 4 Aquatic Chronic 2 H351 H302 H411 GHS08 GHS07 GHS09 Wng H351 H302 H411 606-147-00-2 cycloxydim (ISO); 2-(N-ethoxybutanimidoyl)-3-hydroxy-5-(tetrahydro-2 H -thiopyran-3-yl)cyclohex-2-en-1-one 405-230-9 101205-02-1 Repr. 2 H361d GHS08 Wng H361d 607-705-00-8 benzoic acid 200-618-2 65-85-0 STOT RE 1 Skin Irrit. 2 Eye Dam. 1 H372 (lungs) (inhalation) H315 H318 GHS08 GHS05 Dgr H372 (lungs) (inhalation) H315 H318 607-706-00-3 methyl 2,5-dichlorobenzoate 220-815-7 2905-69-3 Acute Tox. 4 STOT SE 3 Aquatic Chronic 2 H302 H336 H411 GHS07 GHS09 Wng H302 H336 H411 612-287-00-5 fluazinam (ISO); 3-chloro-N-[3-chloro-2,6-dinitro-4-(trifluoromethyl)phenyl]-5-(trifluoromethyl)pyridin-2-amine - 79622-59-6 Repr. 2 Acute Tox. 4 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H361d H332 H318 H317 H400 H410 GHS08 GHS07 GHS05 GHS09 Dgr H361d H332 H318 H317 H410 M = 10 M = 10 613-317-00-X penconazole (ISO); 1-[2-(2,4-dichlorophenyl)pentyl]-1H-1,2,4-triazole 266-275-6 66246-88-6 Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H361d H302 H400 H410 GHS08 GHS07 GHS09 Wng H361d H302 H410 M = 1 M = 1 613-318-00-5 fenpyrazamine (ISO); S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carbothioate - 473798-59-3 Aquatic Chronic 2 H411 GHS09 H411 616-212-00-7 3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate 259-627-5 55406-53-6 Acute Tox. 3 Acute Tox. 4 STOT RE 1 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H331 H302 H372 (larynx) H318 H317 H400 H410 GHS06 GHS08 GHS05 GHS09 Dgr H331 H302 H372 (larynx) H318 H317 H410 M = 10 M = 1’ (2) Table 3.2 is amended as follows: (a) the entry corresponding to index number 015-188-00-X is deleted; (b) the entries corresponding to index numbers 006-086-00-6, 015-154-00-4, 015-192-00-1, 601-023-00-4, 601-026-00-0, 603-061-00-7, 605-001-00-5 and 616-035-00-5 are replaced by the following corresponding entries: ‘006-086-00-6 fenoxycarb (ISO);ethyl [2-(4-phenoxyphenoxy)ethyl]carbamate 276-696-7 72490-01-8 Carc. Cat. 3; R40 N; R50-53 Xn; N R: 40-50/53 S: (2-)22-36/37-60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % 015-154-00-4 ethephon; 2-chloroethylphosphonic acid 240-718-3 16672-87-0 C; R34 Xn; R20/21/22 N; R51-53 C; N R: 20/21/22-34-51/53 S: (1/2-)26-36/37/39-45-61 Xi; R37: 5 % ≤ C < 10 % 015-192-00-1 tetrakis(2,6-dimethylphenyl)- m -phenylene biphosphate 432-770-2 139189-30-3 R43 Xi R: 43 S: (2-)24-37 601-023-00-4 ethylbenzene 202-849-4 100-41-4 F; R11 Xn; R20-48/20-65 F; Xn R: 11-20-48/20-65 S: (2-)16-24/25-29-62 601-026-00-0 styrene 202-851-5 100-42-5 Repr. Cat. 3; R63 Xn; R20-48/20 Xi; R36/38 R10 Xn R: 10-20-36/38-48/20-63 S: (2-)23-36/37-46 Xn; R20: C ≥ 12,5 % Xi; R36/38: C ≥ 12,5 % D 603-061-00-7 tetrahydro-2-furylmethanol; tetrahydrofurfuryl alcohol 202-625-6 97-99-4 Repr. Cat. 2; R61 Repr. Cat. 3; R62 Xi; R36 T R: 36-61-62 S: 45-53 Xi; R36: C ≥ 10 % 605-001-00-5 formaldehyde …% 200-001-8 50-00-0 Carc. Cat. 2; R45 Muta. Cat. 3; R68 T; R23/24/25 C; R34 R43 T R: 23/24/25-34-43-45-68 S: 45-53 T; R23/24/25: C ≥ 25 % Xn; R20/21/22: 5 % ≤ C < 25 % C; R34: C ≥ 25 % Xi; R36/37/38: 5 % ≤ C < 25 % R43: C ≥ 0,2 % B, D 616-035-00-5 cymoxanil (ISO); 2-cyano- N -[(ethylamino)carbonyl]-2-(methoxyimino)acetamide 261-043-0 57966-95-7 Repr. Cat. 3; R62-63 Xn; R22-48/22 R43 N; R50-53 Xn; N R: 22-43-48/22-62-63-50/53 S: (2-)36/37-46-60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 %’ (c) the following entries are inserted in accordance with the order of the entries set out in Table 3.2: ‘050-028-00-2 2-ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate 260-829-0 57583-35-4 Repr. Cat. 3; R63 T; R48/25 Xn; R22 R43 T R: 22-43-48/25-63 S: (1/2-)36/37-45 050-029-00-8 dimethyltin dichloride 212-039-2 753-73-1 Repr. Cat. 3; R63 T+; R26 T; R24/25-48/25 C; R34 T+ R: 24/25-26-34-48/25-63 S: (1/2-)26-28-36/37/39-45-63 601-088-00-9 4-vinylcyclohexene 202-848-9 100-40-3 Carc. Cat. 3; R40 Xn R: 40 S: (2-)36/37 601-089-00-4 muscalure; cis-tricos-9-ene 248-505-7 27519-02-4 R43 Xi R: 43 S: (2-)24-37 604-090-00-8 4-tert-butylphenol 202-679-0 98-54-4 Repr. Cat. 3; R62 Xi; R38-41 Xn R: 38-41-62 S: (2-)26-36/37/39-46 604-091-00-3 etofenprox (ISO); 2-(4-ethoxyphenyl)-2-methylpropyl 3-phenoxybenzyl ether 407-980-2 80844-07-1 R64 N; R50-53 N R: 50/53-64 S: 60-61 N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 % 606-146-00-7 tralkoxydim (ISO); 2-(N-ethoxypropanimidoyl)-3-hydroxy-5-mesitylcyclohex-2-en-1-one – 87820-88-0 Carc. Cat. 3; R40 Xn; R22 N; R51-53 Xn; N R: 22-40-51/53 S: (2-)36/37-60-61 606-147-00-2 cycloxydim (ISO); 2-(N-ethoxybutanimidoyl)-3-hydroxy-5-(tetrahydro-2H-thiopyran-3-yl)cyclohex-2-en-1-one 405-230-9 101205-02-1 F; R11 Repr. Cat. 3; R63 F; Xn R: 11-63 S: (2-)16-36/37-46 607-705-00-8 benzoic acid 200-618-2 65-85-0 T; R48/23 Xi; R38-41 T R: 38-41-48/23 S: (1/2-)26-39-45-63 607-706-00-3 methyl 2,5-dichlorobenzoate 220-815-7 2905-69-3 Xn; R22 N; R51-53 Xn; N R: 22-51/53 S: (2-) 46-61 612-287-00-5 fluazinam (ISO); 3-chloro-N-[3-chloro-2,6-dinitro-4-(trifluoromethyl)phenyl]-5-(trifluoromethyl)pyridin-2-amine - 79622-59-6 Repr. Cat. 3; R63 Xn; R20 Xi; R41 R43 N; R50-53 Xn; N R: 20-41-43-50/53-63 S: (2-)26-36/37/39-46-60-61 N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % 613-317-00-X penconazole (ISO); 1-[2-(2,4-dichlorophenyl)pentyl]-1H-1,2,4-triazole 266-275-6 66246-88-6 Repr. Cat. 3; R63 Xn; R22 N; R50-53 Xn; N R: 22-50/53-63 S: (2-) 36/37-46-60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % 613-318-00-5 fenpyrazamine (ISO); S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carbothioate - 473798-59-3 N; R51-53 N R: 51/53 S: 60-61 616-212-00-7 3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate 259-627-5 55406-53-6 T; R23-48/23 Xn; R22 Xi; R41 R43 N; R50 T; N R: 22-23-41-43-48/23-50 S: (1/2-)24-26-37/39-45-63 N; R50: C ≥ 2,5 %’
Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.